75M vac­cine dos­es wast­ed: FDA spells out Emer­gent fa­cil­i­ty de­fi­cien­cies at length in new memo

The FDA is of­fer­ing a fuller ac­count of what went wrong at Emer­gent BioSo­lu­tions’ Covid-19 man­u­fac­tur­ing fa­cil­i­ty in Bal­ti­more, where the cross con­t­a­m­i­na­tion of J&J and As­traZeneca vac­cines led to the dis­card­ing of about 75 mil­lion vac­cine dos­es.

CBER di­rec­tor Pe­ter Marks re­leased a memo on Sat­ur­day with new specifics, mak­ing clear up front that no vac­cine man­u­fac­tured at this plant has been dis­trib­uted for use in the US yet.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.